Skip to main content
OpenTrials

Clinical trial condition

Haemophilus Influenzae Type b

Explore clinical trials studying Haemophilus Influenzae Type b. Study availability and eligibility vary by location and protocol.

84 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Haemophilus Influenzae Type b trial results

Not yet recruiting

Study of BK1803 in Healthy Infants

NCT07793513

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +36 more
Locations
  • Fukui Aiiku Hospital Fukui-shi, Fukui, Japan
  • Oda Children's Allergy Clinic Fukuoka, Japan
  • Morooka Chirdren's Chikushi-dori Clinic Fukuoka, Japan
  • Shindo children's clinic Fukuoka, Japan
View all 33 locations
View Trial Details
Active, not recruiting

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

NCT06947499

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +36 more
Locations
  • Care CT Group Dasmariñas, Cavite, Philippines
View Trial Details
Completed

Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth

NCT02428491

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +36 more
Locations
  • Preventive Medicine Centre of Thai Binh Province Thái Bình, Vietnam
View Trial Details
Completed

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

NCT01453998

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +32 more
Locations
  • GSK Investigational Site Santo Domingo, Dominican Republic
  • GSK Investigational Site Santo Domingo, Distrito Nacional, Dominican Republic
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
View all 16 locations
View Trial Details

Related conditions